Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo.
We investigated the toxic effect of levofloxacin (LVFX), a quinolone antibacterial agent, on cartilage by examining aspects of its in vivo toxicokinetics and effect on the function of cultured chondrocytes of the femoral articular cartilage from juvenile New Zealand White rabbits. Repeated administration of LVFX (100 mg/kg) orally for 7 days induced focal necrosis and superficial erosion in the articular cartilage of the femoral condyle, but 30 mg/kg did not. Concentrations of LVFX in the cartilage were highest at the first sampling point (30 min) after a single administration, being 4.93 and 12.2 micrograms/g in the 30- and 100-mg/kg groups, respectively. The arthropathic concentration of LVFX in the cartilage was then shown to be 12.2 micrograms/g or more. For an in vitro study, chondrocytes were separated from the articular cartilage of the rabbit femoral condyle and cultured for 7 days until confluence. 35SO4 uptake by cultured chondrocyte sheets was most susceptible to LVFX, decreasing at drug concentrations of 5 micrograms/ml or more in 24- and 48-h cultures but not in a 72-h culture. Furthermore, 3H-thymidine uptake was decreased at concentrations of 10 micrograms/ml or more in a 48-h culture but not in 24- and 72-h cultures. Rhodamine 123 accumulation was susceptible to inhibition in cultured chondrocytes at an LVFX concentration of 10 micrograms/ml or more. These results suggest that LVFX inhibits glycosaminoglycan synthesis initially and DNA synthesis and mitochondrial function secondarily at actual arthropathic concentrations in cultured rabbit chondrocytes but that these changes are reversible and not enough to kill the cells.
Drug Safety Research Center, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
M
M
Kato
S
S
Takada
S
S
Ogawara
S
S
Takayama
D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000633:toxicity*; D002358:Cartilage, Articular / Q000166:cytology / Q000293:injuries / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis*; D006025:Glycosaminoglycans / Q000096:biosynthesis*; D064704:Levofloxacin; D008297:Male; D015242:Ofloxacin / Q000493:pharmacokinetics / Q000633:toxicity*; D011817:Rabbits; D013431:Sulfates / Q000378:metabolism; D013462:Sulfur Radioisotopes; D013936:Thymidine / Q000378:metabolism
D000890:Anti-Infective Agents; D006025:Glycosaminoglycans; D013431:Sulfates; D013462:Sulfur Radioisotopes; D064704:Levofloxacin; D004247:DNA; D015242:Ofloxacin; D013936:Thymidine